marketcap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-12-2025
Cue Biopharma Cash Conversion Cycle 2011-2025 | CUE
Annual Cash Conversion Cycle Cue Biopharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51.9 | 58.3 | 469 | 55.7 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 469 | 51.9 | 159 |
Quarterly Cash Conversion Cycle Cue Biopharma
| 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.8 | - | 68.4 | 60.9 | - | 60.8 | 43.9 | 61.7 | - | 534 | 1.62 K | 186 | - | 51 | 55.2 | 83.2 | - | 184 | 120 | 110 | - | 70 | 65.3 | 93.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.62 K | 22.8 | 194 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
-8.96 K | $ 11.3 | -10.17 % | $ 12.2 K | - |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-204 | $ 4.37 | -1.58 % | $ 28.1 M |  China |
 |
Axon Enterprise
AXON
|
86.2 | $ 716.9 | -0.99 % | $ 54.3 B |  USA |
 |
Caladrius Biosciences
CLBS
|
164 | $ 0.43 | -16.75 % | $ 25.8 M | USA |
 |
Sorrento Therapeutics
SRNE
|
-49.6 K | $ 0.27 | -29.58 % | $ 126 M | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | $ 184.71 | 0.49 % | $ 251 B |  Cayman-islands |
 |
ContraFect Corporation
CFRX
|
-1.83 K | $ 1.47 | -5.16 % | $ 5.39 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
-295 | $ 4.93 | 1.02 % | $ 90.8 M |  Britain |
 |
Midatech Pharma plc
MTP
|
82.8 | $ 0.29 | -18.52 % | $ 27.3 M | Britain |
 |
Advaxis
ADXS
|
-143 K | $ 0.31 | -9.65 % | $ 45.9 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
34.8 | $ 6.2 | - | $ 154 M | USA |
 |
Zymeworks
ZYME
|
211 | $ 6.42 | - | $ 404 M |  Canada |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | $ 5.72 | 5.93 % | $ 314 M | Canada |
 |
Kadmon Holdings, Inc.
KDMN
|
3.92 | $ 9.5 | - | $ 1.7 B | USA |
 |
BioDelivery Sciences International
BDSI
|
340 | $ 2.58 | -4.8 % | $ 255 M | USA |
 |
Zosano Pharma Corporation
ZSAN
|
-884 | $ 0.56 | 7.23 % | $ 2.72 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | $ 0.5 | - | $ 7.46 M |  Israel |
 |
Krystal Biotech
KRYS
|
92.2 | $ 203.41 | 2.81 % | $ 5.82 B | USA |
 |
Acceleron Pharma Inc.
XLRN
|
319 | $ 179.68 | - | $ 10.9 B | USA |
 |
Albireo Pharma
ALBO
|
-1.55 K | $ 44.15 | -0.23 % | $ 916 M | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
246 | $ 18.44 | - | $ 1.94 B | Canada |
 |
Mesoblast Limited
MESO
|
0.01 | $ 15.61 | -3.1 % | $ 10.1 B |  Australia |
 |
Aptinyx
APTX
|
46.9 | $ 0.06 | -39.0 % | $ 4.57 M | USA |
 |
Celyad Oncology SA
CYAD
|
-55.7 K | $ 0.47 | - | $ 12.5 M |  Belgium |
 |
Brickell Biotech
BBI
|
149 | $ 2.11 | -5.38 % | $ 6.06 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | $ 3.17 | 1.93 % | $ 17.4 M | USA |
 |
Calithera Biosciences
CALA
|
28.8 | $ 0.37 | -10.95 % | $ 876 K | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | $ 49.55 | -6.81 % | $ 3.04 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |